SGI-1776

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameSGI-1776
Drug Alias NameSGI-1776SG-0407
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProto-oncogene serine/threonine-protein kinase Pim-1 inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors
TargetsProto-oncogene serine/threonine-protein kinase Pim-1Tyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsProstatic NeoplasmsLymphoma, Non-HodgkinLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstex Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstex Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsProstatic NeoplasmsLymphoma, Non-HodgkinLeukemia

Other Information

ATC CodeN/A
Related LinksN/A